FT : Investors in Afren set to be wiped out

Group dragged down by collapsing oil price, governance abuses and mountain of debt

Investors expecting to retrieve any value from their holdings in Afren, the scandal-hit oil explorer that entered administration last week, are likely to be sorely disappointed.
People familiar with the company are predicting its stakes in key assets such as the Ebok and Okoro oilfields in Nigeria will be taken over by either the Nigerian government or its local business partners.

That pessimism is echoed in Afren’s bonds, which are currently trading as low as 2 cents on the dollar, compared with about 40 cents in June.
“There is a material risk that there might not be much to share at the end of the day,” says Stephane Foucaud, an oil analyst at brokerage FirstEnergy Capital.

announcement last Friday that it had begun insolvency proceedings was the denouement of a complex, protracted drama that brought a once promising oil explorer to its knees. The Nigeria-focused company found itself at the eye of a perfect storm, dragged down by a collapsing oil price, corporate governance abuses and a mountain of debt.
The London-listed explorer had once looked like an African success story. Fields such as Ebok threw off cash, especially when oil was at $100, and retail investors piled into the stock. The company’s market capitalisation grew from $73m when it listed on AIM in 2005 to $2.6bn in March last year.
“It was seen as a highly credible producer which turned round the perception of Nigeria,” said one western energy banker.
Last year, the company’s prospects dramatically changed. In July the board suspended chief executive Osman Shahenshah and chief operating officer, Shahid Ullah over “unauthorised payments” that had come to light in an independent review.
The timing was dire. Afren was heavily in debt, but was just days away from signing a refinancing deal with creditors to relieve some of the pressure on its balance sheet. When the suspicious payments came to light, the banks balked.
In October, the company announced the results of an investigation by law firm Willkie, Farr & Gallagher, which found that Messrs Shahenshah and Ullah had struck a secret financing deal in October 2013 with Oriental, one of Afren’s Nigerian partners. Oriental had agreed to pay 15 per cent of cash flows from the Ebok field over four years to an entity registered in the British Virgin Islands and controlled by Messrs Shahenshah and Ullah. WFG said the two men used the funds to pay “extraordinary bonuses” to themselves. Afren’s board fired them for gross misconduct.
A new temporary chief executive, Toby Hayward, was appointed: but he lacked operational experience of the oil industry. “Afren went into a period where the business did not have clear leadership,” said a person familiar with the company.
Mr Hayward started searching for a saviour. Takeover talks were held with Seplat, a Nigerian oil group, but bondholders were reluctant to take the haircut that would have been needed to complete a deal and discussions were abandoned.
Afren’s string of bad news was becoming longer. In January, it admitted it had overstated its reserves in Barda Rash, an oilfield in Iraqi Kurdistan, reducing its highest estimate from 1.2bn barrels to just 250m.
The share price went into freefall. Having reached 169.30p in late December 2013, by January this year it had fallen to 4.20p. The stock fell again in March when Afren defaulted on a $15m interest payment.
But later that month, Afren’s fortunes briefly looked as if they might improve. The company agreed a recapitalisation plan with its lenders involving $300m of new funding by the end of June and hired Alan Linn, an oil industry veteran, as its new chief executive.
Boosted by $200m in emergency funding from bondholders, Mr Linn set about trying to right the ship. But he soon discovered Afren’s affairs were in an even worse state than previously thought. The cash crunch had led to project delays, so Afren’s near-term production was set to be much lower than assumed in the business plan that formed the basis of its bailout deal. Last month Afren came clean on the production issue and requested that trading in its shares be suspended.

Shareholders were due to vote in July on a rights issue and the issuance of new shares, key elements of the bailout plan. But Afren called off the vote, and told investors they would have to stump up another $250m to keep the company afloat. They refused.
“The bondholders had thrown a lot of money at the problem, but just ran out of patience,” said one person familiar with the company.
By last week, time had run out for Afren. On Friday it called in administrators.
In a statement it said that discussions with lenders, bondholders and partners had “failed to deliver support for a revised refinancing and restructuring proposal that would result in Afren being able to pay its debts as they fall due”.
Now, investors could be wiped out, say people familiar with the company. Afren’s negotiating position is weak because, unlike its partners, it does not own its underlying assets, instead controlling them through technical service contracts or so-called “farm-in” agreements.
“If you default in Nigeria, the assets go to the government or to the indigenous partners who have the licence,” said FirstEnergy Capital’s Mr Foucaud.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: RATE +29.3%, MB +17.7%, ZEN +17.4%, RLOC +15.6%, USNA +15.1%, ( announced BoDs appointed Dave Wentz and Kevin Guest as Co-Chief Executive Officers effective immediately), SCMP +13.5%, ECOM +13.4%, CHUY +12.3%, Z +11.7%, ACLS +9.8%, FSLR +9.7%, ZAGG +8.1%, PLPM +8.1%, OCLR +7.5%, SCMP+7.5%, AWAY +7.3%, PAYC +6.9%, ATVI +6.9%, TSEM +6.9%, SMCI +6.6%, OFIX +6.4%, OFIX +6.4%, TTOO +6.3%, COKE +6.1%, KATE +6%, LC +5.9%, AMSG +5.8%, MSI +5.6%, GNRT +5.2%, WD +5.2%, REXX +5.1%, SPNS +4.7%, ENPH +4.6%, OXGN +4.5%, DNOW +4.4%, AHS +4.2%, RMTI +4%, RTRX +4%, XXIA +3.9%, EYES +3.7%, OAS +3.6%, TSE+3.1%, RDC +2.9%, SYNC +2.5%, CSV +1.8%, UVE +1.6%, CDE +1.5%, CWEI +1.3%, TROX +1.2%, ACHC +1.2%, HZN +1.2%, TRUP +1%, RLH +1%, BXE +1%, PRGO +1%, DVN +0.9%, ATHM +0.9%, DVA +0.7%

M&A news: MSI +7.8% (Silver Lake planning $1 bln investment in MSI, according to NY Times Dealbook; also reported earnings ), SCTY +2% (to acquire ILIOSS, to expand into Mexico)

Select metals/mining stocks trading higher: CLF +4.5%, VALE +2.7%, FCX +2.3%, GOLD +1.9%

Select oil/gas related names showing strength: SDRL +3.9%, LINE +3.8%, RDS.A +1.3%, TOT +1.0%, BP +0.9%

Other news: BIOC +10.5% (announced the launch of its proprietary quantitative Target Selector assay targeting KRAS mutations utilizing a patient's blood sample), ARRY +7.9% (mentioned positively by Jim Cramer), ATEN +6.9% (disclosed that on June 5, 2015, Founder and CEO Lee Chen entered into a written stock trading plan in accordance with Rule 10b5-1 to purchase up to an aggregate of $2 mln of common stock), LC +5.9% ( announces a 43.75 mln share public offering of common stock), ADAT +4.6% (disclosed it will explore strategic and financial alternatives in an effort to enhance shareholder value), AAC +3.8% (Chairman and CEO Michael Cartwright disclosed the purchase of 16.66k shares for ~$343k; Director Darrell Freeman purchases 15k shares for $331k), SPWR +3% (in sympathy with FSLR after earnings), JKS +2.8% (in sympathy with FSLR after earnings), SUNE +2.4% (in sympathy with FSLR after earnings), EA +1.7% (in symp with ATVI earnings), PLUG +1.1% (Axane S.A. (L'Aire Liquide) disclosed 5.64% active stake in 13D filing) SNSS +0.7% (announces that results from its Phase 3 VALOR trial of vosaroxin and cytarabine were published in The Lancet Oncology)

Analyst comments: BHP +4.6% (upgraded to Hold at Liberum), RIO +4.2% (upgraded to Hold at Liberum ), JCP +0.7% (upgraded to Hold from Sell at Evercore ISI
)

>>> SodaStream misses by $0.15, misses on revs

SodaStream misses by $0.15, misses on revs

Reports Q2 (Jun) earnings of $0.17 per share, $0.15 worse than the Capital IQ Consensus Estimate of $0.32; adj. revenues fell 28.0% year/year to $101.7 mln vs the $106.31 mln consensus.
  • "Our second quarter performance was in-line with our expectations. As we previously discussed, the first half of 2015 would be a challenging period due to implementation of our global restructuring and growth plan combined with changes in foreign currency exchange rates. That said, we are proud to have achieved an all-time record of CO2 refills"

>>> Ariad Pharm misses by $0.06, misses on revs; updates 2015 guidance (8.09)

Ariad Pharm misses by $0.06, misses on revs; updates 2015 guidance

  • Reports Q2 (Jun) loss of $0.33 per share, $0.06 worse than the Capital IQ Consensus Estimate of ($0.27); total revenues rose 141.3% year/year to $29.2 mln vs the $31.89 mln consensus.
  • Net product revenues from Iclusig were $27.8 mln, an increase of 134% vs 2Q14 and 16% vs 1Q15. Q2 Iclusig product revenues are comprised of revenues of $21.6 million in the U.S. and $6.2 million in Europe.
  • Co expects Iclusig revenues for 2015 to be in the range of $130-140 million.
  • Co expects its cash & cash equivalents at December 31, 2015 to be at least $240 million.

>>> Valero Energy Partners beats by $0.09, beats on revs

Valero Energy Partners beats by $0.09, beats on revs

Reports Q2 (Jun) earnings of $0.54 per share, $0.09 better than the Capital IQ Consensus Estimate of $0.45; revenues rose 89.3% year/year to $60.2 mln vs the $54.65 mln consensus.
  • On July 24, 2015, the board of directors of VLP's general partner declared a second quarter 2015 cash distribution of $0.2925 per unit. This distribution represents a 5.4 percent increase from the first quarter of 2015 and an increase of 31.5 percent from the second quarter of 2014.

>>> Wendy's reports Q2 (Jun) results, revs in-line; reaffirms FY15 EPS guidance,

Wendy's reports Q2 (Jun) results, revs in-line; reaffirms FY15 EPS guidance, raises margin, EBITDA guidance, lowers comp guidance; reaffirms long term guidance

  • Reports Q2 (Jun) adj. earnings of $0.08 per share, including a $4.1 mln tax item, may not be comparable to the Capital IQ Consensus of $0.09; revenues fell 3.3% year/year to $489.5 mln vs the $487.74 mln consensus.
    • Same-restaurant sales increased 2.4 percent at North America Company-operated restaurants in the second quarter of 2015, while same-restaurant sales increased 2.2 percent at North America franchise-operated restaurants. Systemwide same-restaurant sales increased 2.2 percent during the second quarter of 2015. Higher sales at reimaged Image Activation restaurants contributed ~170 basis points to Company-operated same-restaurant sales results, primarily from increased customer counts.
  • Co reaffirms EPS guidance for FY15, sees EPS of $0.31-0.33, excluding non-recurring items, vs. $0.32 Capital IQ Consensus.
  • The Company is adjusting its 2015 same-restaurant sales outlook at Company-operated restaurants to 2.0 to 2.5% from +2.5-3%.
  • Company is increasing its outlook for 2015 Adjusted EBITDA from continuing operations to $385 to $390 million from its prior guidance of $375 million to $385 million. This represents an increase of 8 to 9 percent compared to the Company's 2014 Adjusted EBITDA results, which exclude the EBITDA contribution attributable to the Company's bakery operations.
  • The Company is also increasing its 2015 outlook for restaurant operating margins by 50 basis points to 17.0 to 17.5 percent, an improvement of ~120 to 170 basis points compared to 15.8 percent in 2014. This estimate includes an improved outlook for commodity costs. The Company now expects its commodity costs to be ~flat compared to 2014.
  • Company reaffirms long-term outlook.

(BofA-ML) AAPL Downgrade to Neutral

Long term winner but iPhone deceleration creates headwinds, move to Neutral

Deceleration in iPhones creates near term headwinds
We downgrade shares of Apple Inc. (ticker: AAPL) to Neutral from Buy with a PO of $130.
Although the long term opportunity is significant, we expect near term pressure on shares
driven by (1) significant slowdown in revenue growth as iPhone growth decelerates and other
initiatives like Apple Watch, Apple Pay, Apple Music take time to ramp, (2) China now
accounts for ~25% of iPhone sales (C2Q) and share gains will be more difficult to come by,
(3) the stock price is correlated to gross profit dollar growth (Figure 6), which despite the
mix benefit of the iPhone will decelerate significantly over the next few quarters, (4) the
magnitude of the beats is diminishing creating higher risk to negative revisions particularly
as the Apple watch expectations are likely too elevated in 2016 , (5) the iPhone 6S/6S+ are
likely to be an incremental upgrade (force touch), but not likely compelling enough for driving
a significant change in the pace of share gains, and (6) we do not see incremental capital
return announcements beyond the already announced plans in the near term.

What about new products – Watch, Apple Pay, Music?
We model $0.30 EPS impact from Apple Watch in C2016 and $0.11 from Apple Pay. At its
current ~10mn subscribers for Apple Music (not yet paying), the contribution will remain
relatively small in C2016 at less than $0.10/share. Although the potential exists for each of
these to become significant revenue drivers in the long-run, the short-to-medium term
direction of the stock remains dependent on the iPhone.

Valuation always compelling; Momentum trumps near term
We do not dispute that valuation metrics remain compelling for Apple; however, in the last
down-cycle despite compelling valuation the stock retraced 30%. AAPL stock has rallied
40% in C14 (vs. S15INFT up 18%), and is trading at multiples at a slight discount to peers.

Where could we be wrong? PO moves to $130
Stronger than expected share gains of iPhones from Android, or increased enterprise
penetration could drive upside relative to our model. Reacceleration in iPad sales could
offset some of the iPhone decline, but with lower margins. Our new PO of $130 is based on
13x C2016 EPS of $9.99.

(BFW) Activist Fund Cevian Has Over 13% Interest in Zurich Target RSA


BN 08/05 11:14 *CEVIAN HAS 13.54% INTEREST IN RSA VIA SHARES, DERIVATIVES
BN 08/05 11:10 *CEVIAN CAP II GP LTD FORM 8.3 - RSA INSURANCE GROUP

Activist Fund Cevian Has Over 13% Interest in Zurich Target RSA
2015-08-05 11:19:57.548 GMT


By Gaurav Panchal
(Bloomberg) -- Activist investor Cevian has 13.54% interest
in RSA via shares, derivatives, according to filing.

* Exposure via shares 9.67%, cash-settled derivatives 3.86%
* Filing Link
* April 25: Cevian Capital holds a stake of more than 10% in
RSA, Sky reported Link
* Aug. 3: RSA Hits 2013 High as Zurich Said to Prepare
Financing for Bid Link



Link to Company News:{789633Z SS <Equity> CN <GO>}
Link to Company News:{3823096Z JY <Equity> CN <GO>}
Link to Company News:{RSA LN <Equity> CN <GO>}
Link to Company News:{ZURN VX <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the editor responsible for this story:
Gaurav Panchal at +44-20-3525-0511 or
gpanchal2@bloomberg.net